Stoke Therapeutics, Inc. (STOK) Form 8-K — Sep 25, 2026
Stoke Therapeutics disclosed that Edward M. Kaye, M.D. resigned as a Class III director and R&D Committee member effective September 23, 2026, stating his resignation was not due to any disagreement with the company. The board appointed Alexander (Bo) Cumbo as an independent Class III director on the same day to fill the vacancy, with a term expiring at the 2028 annual meeting.
Key figures
- Stock Option Shares
- 39674
- Annual Cash Retainer
- 45000
- Stock Option Fair Value
- 724000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.